Cargando…

Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer

Cell therapy encompasses an expanding spectrum of cell-based regimes for the treatment of human ailments, such as the use of immune cells, in particular T cells, for combating tumors and the modulation of inflammatory immune responses. In this review, we focus on cell therapy in the immuno-oncology...

Descripción completa

Detalles Bibliográficos
Autores principales: Neo, Shi Yong, Xu, Shengli, Chong, Joni, Lam, Kong-Peng, Wu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151952/
https://www.ncbi.nlm.nih.gov/pubmed/37100458
http://dx.doi.org/10.1136/jitc-2022-006434
_version_ 1785035651643604992
author Neo, Shi Yong
Xu, Shengli
Chong, Joni
Lam, Kong-Peng
Wu, Jing
author_facet Neo, Shi Yong
Xu, Shengli
Chong, Joni
Lam, Kong-Peng
Wu, Jing
author_sort Neo, Shi Yong
collection PubMed
description Cell therapy encompasses an expanding spectrum of cell-based regimes for the treatment of human ailments, such as the use of immune cells, in particular T cells, for combating tumors and the modulation of inflammatory immune responses. In this review, we focus on cell therapy in the immuno-oncology space, which is largely driven by interests and demands from the clinics for better solutions to target various hard-to-treat cancers. We discuss recent advances in various types of cell therapies, including T cell receptor-T cells, chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes and natural killer cells. Particularly, the present review focuses on the strategies to improve therapeutic responses by either enhancing tumor recognition or the resilience of infused immune cells within tumor microenvironment. Finally, we discuss the potential of other innate or innate-like immune cell types currently being explored as promising CAR-cell alternatives that seek to address the limitations of conventional adoptive cell therapies.
format Online
Article
Text
id pubmed-10151952
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-101519522023-05-03 Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer Neo, Shi Yong Xu, Shengli Chong, Joni Lam, Kong-Peng Wu, Jing J Immunother Cancer Review Cell therapy encompasses an expanding spectrum of cell-based regimes for the treatment of human ailments, such as the use of immune cells, in particular T cells, for combating tumors and the modulation of inflammatory immune responses. In this review, we focus on cell therapy in the immuno-oncology space, which is largely driven by interests and demands from the clinics for better solutions to target various hard-to-treat cancers. We discuss recent advances in various types of cell therapies, including T cell receptor-T cells, chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes and natural killer cells. Particularly, the present review focuses on the strategies to improve therapeutic responses by either enhancing tumor recognition or the resilience of infused immune cells within tumor microenvironment. Finally, we discuss the potential of other innate or innate-like immune cell types currently being explored as promising CAR-cell alternatives that seek to address the limitations of conventional adoptive cell therapies. BMJ Publishing Group 2023-04-26 /pmc/articles/PMC10151952/ /pubmed/37100458 http://dx.doi.org/10.1136/jitc-2022-006434 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Neo, Shi Yong
Xu, Shengli
Chong, Joni
Lam, Kong-Peng
Wu, Jing
Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer
title Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer
title_full Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer
title_fullStr Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer
title_full_unstemmed Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer
title_short Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer
title_sort harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151952/
https://www.ncbi.nlm.nih.gov/pubmed/37100458
http://dx.doi.org/10.1136/jitc-2022-006434
work_keys_str_mv AT neoshiyong harnessingnovelstrategiesandcelltypestoovercomeimmunetoleranceduringadoptivecelltherapyincancer
AT xushengli harnessingnovelstrategiesandcelltypestoovercomeimmunetoleranceduringadoptivecelltherapyincancer
AT chongjoni harnessingnovelstrategiesandcelltypestoovercomeimmunetoleranceduringadoptivecelltherapyincancer
AT lamkongpeng harnessingnovelstrategiesandcelltypestoovercomeimmunetoleranceduringadoptivecelltherapyincancer
AT wujing harnessingnovelstrategiesandcelltypestoovercomeimmunetoleranceduringadoptivecelltherapyincancer